Боль начиналась с коренных зубов нижней челюсти, переходила на верхнюю, к уху, к глазу и дальше вверх. Выпила весь анальгин и Пенталгин, что были в аптечке, но безрезультатно. И тут на глаза попалась настойка эхинацеи. Как только начинался приступ боли, наливала чайную ложку настойки и половину выливала на нижнюю челюсть, а второй половиной растирала щеку по ходу нерва вверх. Делала так 3-4 раза в день. За три дня, слава Богу, все прошло.
Rituximab (a humanized anti-CD20 monoclonal antibody) is a
helpful remedy for Epstein-Barr virus-associated put up transplant lymphoproliferative disease (EBV-PTLD).
Nonetheless, hypogammaglobulinemia is a complication associated with this remedy.1,2 Little is thought about the duration and severity
of rituximab-induced low serum immunoglobulin (Ig) standing.
EBV-PTLD. One of three patients reported by Verschuuren et al1 died
of invasive aspergillosis as a consequence
of hypogammaglobulinemia after 7 months of rituximab therapy.
Tax calculation might be finalised throughout checkout.
Get time restricted or full article access on ReadCube. All costs
are Internet costs. Verschuuren EA, Stevens SJ, van Imhoff GW et al.
Therapy of posttransplant lymphoproliferative illness with rituximab: the remission, the relapse, and the complication.
Quartier P, Brethon B, Philippet P et al. Therapy of childhood
autoimmune haemolytic anaemia with rituximab. Castagnola E, Dallorso S, Faraci M et al.
Long-lasting hypogammaglobulinemia following rituximab
administration for Epstein-Barr virus-related put up-transplant
lymphoproliferative disease preemptive therapy. Imashuku S, Naya M,
Tamura S et al. Effectiveness of rituximab for chemotherapy-resistant multiple tumoral B-LPD in a haematopoietic stem cell recipient.
Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20
monoclonal antibody (rituximab) in publish-transplant B-lymphoproliferative disorder following
stem cell transplantation in children. Esser JWJ, Niesters HGM, van der Holt B et al.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in excessive-risk patients after allogeneic stem cell transplantation. Kuehnle I, Huls MH,
Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Imashuku,
S., Teramura, T., Morimoto, A. et al. Prolonged hypogammaglobulinemia
following rituximab therapy for submit transplant Epstein-Barr virus-associated lymphoproliferative illness.